Resumen
Introducción: la depresión es un trastorno psiquiátrico prevalente que impacta significativamente la calidad de vida de los individuos afectados. A pesar de los avances en los tratamientos farmacológicos, existen limitaciones tanto en su eficacia como en la duración de sus efectos terapéuticos. En este contexto, la psilocibina ha emergido como una herramienta prometedora en intervenciones psicoterapéuticas asistidas, lo que ha impulsado un creciente interés en su estudio dentro de modelos clínicos integrados.
Materiales y métodos: se realizó una revisión de la literatura actual sobre los efectos de la psilocibina en el tratamiento de la depresión. Se incluyeron estudios clínicos y experimentales que documentan los efectos cognitivos y conductuales de la psilocibina en voluntarios sanos y en pacientes con trastorno depresivo mayor, así como los mecanismos moleculares involucrados.
Resultados: los estudios revisados sugieren que la psilocibina modula los receptores de serotonina 5-HT2A y reorganiza las redes cerebrales asociadas con el procesamiento emocional y la autorregulación. Las pruebas neuropsicológicas iniciales indican que la psilocibina facilita la presencia de un sesgo positivo en el procesamiento emocional.
Discusión: los hallazgos indican que la psilocibina no solo presenta efectos antidepresivos, sino que también promueve una mayor adaptación psicológica mediante la modificación de la conectividad cerebral. La combinación de psilocibina con psicoterapia podría potenciar los cambios en la flexibilidad psicológica y en la regulación emocional.
Conclusiones: la psilocibina muestra un potencial terapéutico relevante en el manejo de la depresión; sin embargo, resulta necesario investigar más a fondo sus efectos a largo plazo y su posible integración en tratamientos convencionales.
Citas
Carhart-Harris R, Giribaldi B, Watts R, Baker-Jones M, Murphy-Beiner A, Murphy R, et al. Trial of psilocybin versus escitalopram for depression. N Engl J Med. 2021;384(15):1402–11. https://doi.org/10.1056/NEJMoa2032994
Lowe H, Toyang N, Steele B, Valentine H, Grant J, Ali A, et al. The therapeutic potential of psilocybin. Molecules. 2021;26(10):2948. https://doi.org/10.3390/molecules26102948
Serrano-Hurtado DS. La psilocibina: Perspectiva histórica y farmacológica e investigaciones actuales autorizadas. Culturaydroga [Internet]. 2009;14(16):165-88. https://revistasojs.ucaldas.edu.co/index.php/culturaydroga/article/view/5437
Carhart-Harris RL, Bolstridge M, Day CMJ, Rucker J, Watts R, Erritzoe DE, et al. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology. 2018;235(2):399–408. https://doi.org/10.1007/s00213-017-4771-x
Goodwin GM, Aaronson ST, Alvarez O, Arden PC, Baker A, Bennett JC, et al. Single-dose psilocybin for a treatment-resistant episode of major depression. N Engl J Med. 2022;387(18):1637–48. https://doi.org/10.1056/NEJMe2210975
Aaronson ST, Van Der Vaart A, Miller T, LaPratt J, Swartz K, Shoultz A, et al. Single-dose synthetic psilocybin with psychotherapy for treatment-resistant bipolar type II major depressive episodes: A nonrandomized open-label trial. JAMA Psychiatry. 2024;81(6):555. https://doi.org/10.1001/jamapsychiatry.2023.4685
American Psychiatric Association. Spanish edition of the desk reference to the diagnostic criteria from DSM-5. American Psychiatric Publishing, Inc; 2013.
World Health Organization (WHO). Depresión [Internet]. [Citado 2024 ago 26] https://www.who.int/es/news-room/fact-sheets/detail/depression
Institute for Health Metrics and Evaluation (IHME). Global burden of disease collaborative network. [Internet]. 2024 [citado 2024 ago 26] https://vizhub.healthdata.org/gbd-results
Tiller JWG. Depression and anxiety. Med J Aust. 2013;199(S6):S28–31. https://doi.org/10.5694/mja12.10628
Zhang Y, Chen Y, Ma L. Depression and cardiovascular disease in elderly: Current understanding. J Clin Neurosci. 2018;47:1–5. https://doi.org/10.1016/j.jocn.2017.09.022
Campayo A, Gómez-Biel CH, Lobo A. Diabetes and depression. Curr Psychiatry Rep. 2011;13(1):26–30. https://doi.org/10.1007/s11920-010-0165-z
Gukasyan N, Davis AK, Barrett FS, Cosimano MP, Sepeda ND, Johnson MW, et al. Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up. J Psychopharmacol. 2022;36(2):151–8. https://doi.org/10.1177/02698811211073759
Davis AK, Barrett FS, May DG, Cosimano MP, Sepeda ND, Johnson MW, et al. Effects of psilocybin-assisted therapy on major depressive disorder: A randomized clinical trial. JAMA Psychiatry. 2021;78(5):481. https://doi.org/10.1001/jamapsychiatry.2020.3285
Ross S, Bossis A, Guss J, Agin-Liebes G, Malone T, Cohen B, et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. J Psychopharmacol. 2016;30(12):1165–80. https://doi.org/10.1177/0269881116675512
Thomann J, Kolaczynska KE, Stoeckmann OV, Rudin D, Vizeli P, Hoener MC, et al. In vitro and in vivo metabolism of psilocybin’s active metabolite psilocin. Front Pharmacol. 2024;15:1391689. https://doi.org/10.3389/fphar.2024.1391689
MacCallum CA, Lo LA, Pistawka CA, Deol JK. Therapeutic use of psilocybin: Practical considerations for dosing and administration. Front Psychiatry. 2022;13:1040217. https://doi.org/10.3389/fpsyt.2022.1040217
Dinis-Oliveira RJ. Metabolism of psilocybin and psilocin: Clinical and forensic toxicological relevance. Drug Metab Rev. 2017;49(1):84–91. https://doi.org/10.1080/03602532.2016.1278228
Shah FI, Shehzadi S, Akram F, Haq IU, Javed B, Sabir S, et al. Unveiling the psychedelic journey: An appraisal of psilocybin as a profound antidepressant therapy. Mol Biotechnol. 2023;67:36-53. https://doi.org/10.1007/s12033-023-00994-7
Cameron LP, Benetatos J, Lewis V, Bonniwell EM, Jaster AM, Moliner R, et al. Beyond the 5-HT2A receptor: Classic and nonclassic targets in psychedelic drug action. J Neurosci. 2023;43(45):7472–82. https://doi.org/10.1523/JNEUROSCI.1384-23.2023
Wallach J, Cao AB, Calkins MM, Heim AJ, Lanham JK, Bonniwell EM, et al. Identification of 5-HT2A receptor signaling pathways associated with psychedelic potential. Nat Commun. 2023;14(1):8221. https://doi.org/10.1038/s41467-023-44016-1
Halberstadt AL, Vollenweider FX, Nichols DE. Behavioral neurobiology of psychedelic drugs. Springer Berlin Heidelberg; 2018. https://doi.org/10.1007/978-3-662-55880-5
Koga Y, Tsurumaki H, Aoki-Saito H, Sato M, Yatomi M, Takehara K, et al. Roles of cyclic AMP response element binding activation in the ERK1/2 and P38 MAPK signalling pathway in central nervous system, cardiovascular system, osteoclast differentiation and mucin and cytokine production. IJMS. 2019;20(6):1346. https://doi.org/10.3390/ijms20061346
Song M, Finley SD. ERK and AKT exhibit distinct signaling responses following stimulation by pro-angiogenic factors. Cell Commun Signal. 2020;18(1):114. https://doi.org/10.1186/s12964-020-00595-w
Vargas-Ibarra D, Velez-Vasquez M, Bermudez-Munoz M. Regulation of MAPK ERK1/2 signaling by phosphorylation: implications in physiological and pathological contexts [Internet]. In: Ying S. ed. Post-translational modifications in cellular functions and diseases. IntechOpen; 2021. http://dx.doi.org/10.5772/intechopen.97061
De Vos CMH, Mason NL, Kuypers KPC. Psychedelics and neuroplasticity: A systematic review unraveling the biological underpinnings of psychedelics. Front Psychiatry. 2021;12:724606. https://doi.org/10.3389/fpsyt.2021.724606
Schmidt M, Hoffrichter A, Davoudi M, Horschitz S, Lau T, Meinhardt M, et al. Psilocin fosters neuroplasticity in iPSC-derived human cortical neurons. Res Square. 2024. https://doi.org/10.21203/rs.3.rs-4242829/v1
Xiang D, Wang H, Sun S, Yao L, Li R, Zong X, et al. GRP receptor regulates depression behavior via interaction with 5-HT2A receptor. Front Psychiatry [Internet]. 2020;10(2019). https://doi.org/10.3389/fpsyt.2019.01020
Vargas MV, Dunlap LE, Dong C, Carter SJ, Tombari RJ, Jami SA, et al. Psychedelics promote neuroplasticity through the activation of intracellular 5-HT2A receptors. Science. 2023;379(6633):700–6. https://doi.org/10.1126/science.adf0435
Moliner R, Girych M, Brunello CA, Kovaleva V, Biojone C, Enkavi G, et al. Psychedelics promote plasticity by directly binding to BDNF receptor TrkB. Nat Neurosci. 2023;26(6):1032–41. https://doi.org/10.1038/s41593-023-01316-5
Kraehenmann R, Preller KH, Scheidegger M, Pokorny T, Bosch OG, Seifritz E, et al. Psilocybin-induced decrease in amygdala reactivity correlates with enhanced positive mood in healthy volunteers. Biol Psychiatry. 2015;78(8):572–81. https://doi.org/10.1016/j.biopsych.2014.04.010
Murphy SE, Norbury R, O’Sullivan U, Cowen PJ, Harmer CJ. Effect of a single dose of citalopram on amygdala response to emotional faces. Br J Psychiatry. 2009;194(6):535–40. https://doi.org/10.1192/bjp.bp.108.056093
Carhart-Harris RL, Roseman L, Bolstridge M, Demetriou L, Pannekoek JN, Wall MB, et al. Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. Sci Rep. 2017;7(1):13187. https://doi.org/10.1038/s41598-017-13282-7
Uddin LQ. Cognitive and behavioural flexibility: Neural mechanisms and clinical considerations. Nat Rev Neurosci. 2021;22(3):167–79. https://doi.org/10.1038/s41583-021-00428-w
Mertens LJ, Wall MB, Roseman L, Demetriou L, Nutt DJ, Carhart-Harris RL. Therapeutic mechanisms of psilocybin: Changes in amygdala and prefrontal functional connectivity during emotional processing after psilocybin for treatment-resistant depression. J Psychopharmacol. 2020;34(2):167–80. https://doi.org/10.1177/0269881119895520
Daws RE, Timmermann C, Giribaldi B, Sexton JD, Wall MB, Erritzoe D, et al. Increased global integration in the brain after psilocybin therapy for depression. Nat Med. 2022;28(4):844–51. https://doi.org/10.1038/s41591-022-01744-z
Copa D, Erritzoe D, Giribaldi B, Nutt D, Carhart-Harris R, Tagliazucchi E. Predicting the outcome of psilocybin treatment for depression from baseline fMRI functional connectivity. J Affect Disord. 2024;353:60–9. https://doi.org/10.1016/j.jad.2024.02.089
Stoliker D, Novelli L, Vollenweider FX, Egan GF, Preller KH, Razi A. Neural mechanisms of resting-state networks and the amygdala underlying the cognitive and emotional effects of psilocybin. Biolog Psychiatry. 2024;96(1):57–66. https://doi.org/10.1016/j.biopsych.2024.01.002
Vohryzek J. Brain dynamics predictive of response to psilocybin for treatment-resistant depression. Brain Commun. 2024;6(2):fcae049. https://doi.org/10.1093/braincomms/fcae049
Roseman L, Demetriou L, Wall MB, Nutt DJ, Carhart-Harris RL. Increased amygdala responses to emotional faces after psilocybin for treatment-resistant depression. Neuropharmacology. 2018;142:263–9. https://doi.org/10.1016/j.neuropharm.2017.12.041
Wall MB, Harding R, Zafar R, Rabiner EA, Nutt DJ, Erritzoe D. Neuroimaging in psychedelic drug development: Past, present, and future. Mol Psychiatry. 2023;28(9):3573–80. https://doi.org/10.1038/s41380-023-02271-0
Hasler F, Grimberg U, Benz MA, Huber T, Vollenweider FX. Acute psychological and physiological effects of psilocybin in healthy humans: A double-blind, placebo-controlled dose? effect study. Psychopharmacology. 2004;172(2):145–56. https://doi.org/10.1007/s00213-003-1640-6
Wittmann M, Carter O, Hasler F, Cahn BR, Grimberg U, Spring P, et al. Effects of psilocybin on time perception and temporal control of behaviour in humans. J Psychopharmacol. 2007;21(1):50–64. https://doi.org/10.1177/0269881106065859
Vollenweider FX, Csomor PA, Knappe B, Geyer MA, Quednow BB. The effects of the preferential 5-HT2A agonist psilocybin on prepulse inhibition of startle in healthy human volunteers depend on interstimulus interval. Neuropsychopharmacol. 2007;32(9):1876–87. https://doi.org/10.1038/sj.npp.1301324
Quednow BB, Kometer M, Geyer MA, Vollenweider FX. Psilocybin-induced deficits in automatic and controlled inhibition are attenuated by ketanserin in healthy human volunteers. Neuropsychopharmacol. 2012;37(3):630–40. https://doi.org/10.1038/npp.2011.228
Kometer M, Schmidt A, Bachmann R, Studerus E, Seifritz E, Vollenweider FX. Psilocybin biases facial recognition, goal-directed behavior, and mood state toward positive relative to negative emotions through different serotonergic subreceptors. Biolog Psychiatry. 2012;72(11):898–906. https://doi.org/10.1016/j.biopsych.2012.04.005
Davis AK, Barrett FS, May DG, Cosimano MP, Sepeda ND, Johnson MW, et al. Effects of psilocybin-assisted therapy on major depressive disorder: A randomized clinical trial. JAMA Psychiatry. 2021;78(5):481. https://doi.org/10.1001/jamapsychiatry.2020.3285
Zeifman RJ, Wagner AC, Monson CM, Carhart-Harris RL. How does psilocybin therapy work? An exploration of experiential avoidance as a putative mechanism of change. J Affect Disord. 2023;334:100–12. https://doi.org/10.1016/j.jad.2023.04.105
Sloshower J, Zeifman RJ, Guss J, Krause R, Safi-Aghdam H, Pathania S, et al. Psychological flexibility as a mechanism of change in psilocybin-assisted therapy for major depression: Results from an exploratory placebo-controlled trial. Sci Rep. 2024;14(1):8833. https://doi.org/10.1038/s41598-024-58318-x
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.